| abstract |
The present invention relates to the use of the neutralized prolactin receptor antibody 006-H08, and its mature form, and antigen-binding fragments, pharmaceutical compositions containing it, and benign disorders and indications mediated by prolactin receptors such as endometriosis, adenomyosis, In the treatment or prophylaxis of female contraceptive, benign breast disease and breast cancers, lactation inhibition, benign prostatic hyperplasia, fibrosis, high- and normal prolactinemia, and co-therapy in combination hormone therapy to inhibit mammary epithelial cell proliferation Lt; / RTI > The antibodies of the present invention block prolactin receptor-mediated signal transduction. |